Design Therapeutics (DSGN) Net Margin (2020)

Design Therapeutics' (DSGN) quarterly Net Margin came in at 11700.0% in Q4 2020, up 1.8% quarter-over-quarter from 11915.0% in Q3 2020.

Design Therapeutics (DSGN) Net Margin (2020) Analysis & Trends

Design Therapeutics has disclosed Net Margin across 1 years of filings, most recently posting 11700.0% for Q4 2020.

Net Margin for Q4 2020 came in at 11700.0%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was 3685.84% (changed N/A YoY), and the FY2020 annual result was 3685.84%, changed N/A from the prior year.
Net Margin came in at 11700.0% for Q4 2020 at Design Therapeutics, up from 11915.0% in the prior quarter.
In the past five years, Net Margin ranged from a high of 438.73% in Q1 2020 to a low of 11915.0% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	0.82%
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	34.53%
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Design Therapeutics	672.71 Mn	449.88 Mn	-	-

Download Data